Abstracts at any potential DVT-related clinical event [DRCE]), and archivist-coded hospitalisation summaries. Utilization was grouped by resource-type and summed. Stratified analyses were performed by age, gender, DVT site (proximal/distal), and patient location (in-patient/out-patient). RESULTS: At diagnosis, mean age was 57 years, 48% were male, 1/3 were in-patients and 55% had proximal DVT. By 4 months, 17% of patients had ≥1 new hospitalisation, 24% had been investigated for a DRCE and there were a mean of 0.9 emergency department visits, 3.4 family physician visits, 5.2 specialist physician visits and 13.4 episodes of use of paramedical services. Half of patients had purchased elastic stockings, and 69% were still taking warfarin. By 1 month, 31% and 17% of patients reported cutting down on household and work activities, respectively; at 4 months, these figures were 15% and 7%. There was an average loss of 7.3 workdays during the 4-month period. CONCLUSIONS: Although usually considered an acute condition, DVT is associated with significant utilization of resources and loss of productivity for at least 4 months after diagnosis. The longterm economic impact of DVT should be further quantified and factored into cost-effectiveness studies of strategies to prevent or treat DVT. OBJECTIVE: To generate estimates of the costeffectiveness of thromboprophylaxis with enoxaparin versus no thromboprophylaxis (usual care) in patients with acute medical illness in the health care setting of Brazil from the perspective of the public Brazilian health care system. METHODS: Markov process analysis techniques were used to model the health economic outcomes. Data on probabilities of clinical events were derived from clinical trial data from the MEDENOX trial, other published literature and OECD (Organisation for Economic Co-Operation and Development) country-specific population mortality data; units of health care utilization were derived from the Delphi panels; prices and tariffs were derived from official lists. RESULTS: Analysis over a 1-year period showed that the cost per VTE event avoided was REAL 2349 (US$870; €906) and the cost per life saved was REAL 8296 (US$3073; €3201), when assuming no higher risk for morbidity and mortality for asymptomatic patients. The lifetime model (again, assuming no higher risk for recurrence of VTE for asymptomatic patients), showed that the use of enoxaparin leads to a cost per VTE event avoided of REAL 2194 (US$813; €846) and cost per life year gained of REAL 574 (US$213; €221). The lifetime model, which assumes a higher risk of VTE recurrence in asymptomatic patients, leads to a cost of REAL 317 (US$117; €122) per VTE event avoided and REAL 90 (US$33; €35) per life year gained. CONCLUSION: The results showed that the favourable clinical benefit of enoxaparin results in positive short and long-term health economic benefits.
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COST-EFFECTIVENES OF ENOXAPARIN AS THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS IN BRAZIL
OBJECTIVE:
To generate estimates of the costeffectiveness of thromboprophylaxis with enoxaparin versus no thromboprophylaxis (usual care) in patients with acute medical illness in the health care setting of Brazil from the perspective of the public Brazilian health care system. METHODS: Markov process analysis techniques were used to model the health economic outcomes. Data on probabilities of clinical events were derived from clinical trial data from the MEDENOX trial, other published literature and OECD (Organisation for Economic Co-Operation and Development) country-specific population mortality data; units of health care utilization were derived from the Delphi panels; prices and tariffs were derived from official lists. RESULTS: Analysis over a 1-year period showed that the cost per VTE event avoided was REAL 2349 (US$870; €906) and the cost per life saved was REAL 8296 (US$3073; €3201), when assuming no higher risk for morbidity and mortality for asymptomatic patients. The lifetime model (again, assuming no higher risk for recurrence of VTE for asymptomatic patients), showed that the use of enoxaparin leads to a cost per VTE event avoided of REAL 2194 (US$813; €846) and cost per life year gained of REAL 574 (US$213; €221). The lifetime model, which assumes a higher risk of VTE recurrence in asymptomatic patients, leads to a cost of REAL 317 (US$117; €122) per VTE event avoided and REAL 90 (US$33; €35) per life year gained. CONCLUSION: The results showed that the favourable clinical benefit of enoxaparin results in positive short and long-term health economic benefits.
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COST OF MANAGING UNSTABLE ANGINA PATIENTS OVER A NINE-MONTH PERIOD: A EUROPEAN APPROACH Gabriel S, Spiesser J, Jourdan S, Carita P Sanofi-Synthelabo, Bagneux, France OBJECTIVES: While the cost of managing patients with myocardial infarction has been extensively studied, few data are available on the cost of managing unstable angina (UA) patients. The aim of the study was to assess the cost of UA patients in six European countries (France, Belgium, Italy, Spain, Sweden, UK). METHODS: A cohort simulation model was used. Patients entered the model when hospitalised for UA. Resources use during initial hospitalisation (length of stay, invasive procedures) was extracted from a prospective database. The frequency and type of following rehospitalisations for cardiovascular events were derived from a recent clinical trial. The time horizon was nine months and the perspective was that of the health care system. The hospital costs used for each country were based on the local DRG system. Official costs of outpatient medications were used. All costs are expressed for year 2001. RESULTS: The global cost of managing UA patients over a nine-month period was divided in three parts: cost of initial hospitalisation, cost of subsequent hospitalisations and cost of medications. Total length of stay of initial hospitalisation ranges from 7.2 days in Sweden to 10.8 days in Spain. The number of days in intensive care unit ranges from 1.6 in UK to 3.8 in Italy. In France, the global cost was estimated at €7471 per patient, breakdown of cost was as follows: initial hospitalisation (57%), subsequent hospitalisations (33%), medications (10%). For other countries, the global cost per patient was as follows: Belgium €6987, UK £3083, Italy €6908, Spain €6633, Sweden SEK 57608, with a consistent breakdown across countries. CONCLUSION: First hospitalisation is the main cost driver. Nevertheless the cost of subsequent hospitalisations accounts for about one third of the total cost highlighting the need for preventive treatment of subsequent cardiovascular events in UA patients.
